Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 801–900 of 1,001
Peptidosteroid Tweezers Revisited: DNA Binding Through an Optimised Design
Carrette, L. L. G., Morii, T., & Madder, A. (2014) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201301854 · Cited by 12
Lyu, M.-A., Sung, B., Cheung, L. H., Marks, J. W., Aggarwal, B. B., Aguiar, R. C. T., & Rosenblum, M. G. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.017 · Cited by 12
Lacreusette, A., Barbieux, I., Nguyen, J., Pandolfino, M., Dréno, B., Jacques, Y., Godard, A., & Blanchard, F. (2008) · The Journal of Pathology · doi:10.1002/path.2490 · Cited by 12
“In contrast, constitutive activation of STAT3 and its role in tumour cell survival, proliferation, angiogenesis, metastasis and immune evasion, has been observed in numerous cancers [25].”
BackgroundSystematic identification of transcription factors associated with patient survival in cancers
Cheng, C., Li, L. M., Alves, P., & Gerstein, M. (2009) · BMC Genomics · doi:10.1186/1471-2164-10-225 · Cited by 12
“Aberrant expression or activation/inactivation of TFs has been implicated in a variety of human cancer types [3-6].”
STAT3 activates the anti-apoptotic form of caspase 9 in oncovirus-infected B lymphocytes
Koganti, S. R. K., Burgula, S., & Bhaduri‐McIntosh, S. (2019) · Virology · doi:10.1016/j.virol.2019.11.017 · Cited by 12
Sarfraz, M., Afzal, A., Khattak, S., Saddozai, U. A. K., Li, H., Zhang, Q., Madni, A., Haleem, K. S., Duan, S., Wu, D., et al. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.30011 · Cited by 14
“Our previous studies describe that PCNP mediates the prolifera- tion, migration, and invasion of human neuroblastoma, ovarian cancer cells, and lung adenocarcinoma cells through MAPK and PI3K/AKT/ mTOR signaling pathways (Dong et al., 2020; Wang et al., 2019; Wu et al., 2018).”
BackgroundNanomolar Inhibitors of the Transcription Factor STAT5b with High Selectivity over STAT5a
Elumalai, N., Berg, A., Natarajan, K., Scharow, A., & Berg, T. (2015) · Angewandte Chemie · doi:10.1002/ange.201410672 · Cited by 12
Vízkeleti, L., & Spisák, S. (2023) · Cells · doi:10.3390/cells12131745 · Cited by 12
Ren, Z., Aerts, J. L., Pen, J. J., Heirman, C., Breckpot, K., & Grève, J. D. (2014) · Oncogene · doi:10.1038/onc.2014.109 · Cited by 15
Small molecule inhibition of FOXM1: How to bring a novel compound into genomic context
Marsico, G., & Gormally, M. V. (2014) · Genomics Data · doi:10.1016/j.gdata.2014.10.012 · Cited by 12
“Published by Elsevier Inc a b s t r a c t a r t i c l e i n f o Article history: Received 7 October 2014 Accepted 11 October 2014 Available online 22 October 2014 Keywords: Small molecule inhibition RNA-Seq Genomics Transcription FOXM1 Deregulation of transcription factor (TF) networks is emerging as amajor pathogenic…”
BackgroundHepp, M. I., Escobar, D., Farkas, C., Hermosilla, V. E., Álvarez, C., Amigo, R., Gutiérrez, J. L., Castro, A. F., & Pincheira, R. (2018) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2018.05.002 · Cited by 11
Computational Competitive and Negative Design To Derive a Specific cJun Antagonist
Lathbridge, A., & Mason, J. M. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00782 · Cited by 11
Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
Li, C., Zhang, J., Wu, Q., Kumar, A., Pan, G., & Kelvin, D. J. (2023) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-22-0159 · Cited by 13
“In many cancers, TFs are the most direct and promising targets, but the development of related inhibitors has seldom achieved results (53).”
BackgroundSequence-selective DNA binding with cell-permeable oligoguanidinium–peptide conjugates
Mosquera, J., Sánchez, M. I., Valero, J., de Mendoza, J., Vázquez, M. E., & Mascarenas, J. L. (2015) · Chemical Communications · doi:10.1039/c4cc09525a · Cited by 11
Fung, J. J., Kosaka, A. H., Shan, X., Danet-Desnoyers, G. A., Gormally, M. V., Owen, K. A., & Reproducibility Project: Cancer Biology (2015) · eLife · doi:10.7554/elife.08997 · Cited by 11
“Bromodomain and extra terminal (BET) proteins are transcriptional regulators that epigenetically control the expression of genes involved in cell cycle, growth and inflammation (Darnell, 2002; Wu and Chiang, 2007; LeRoy et al., 2008; Dey et al., 2009; Nicodeme et al., 2010).”
BackgroundLaughlin, S., Carter, K., Ivanov, I. N., & Wilson, W. D. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw1232 · Cited by 14
Gervais, V., Muller, I., Mari, P., Mourcet, A., Movellan, K. T., Ramos, P., Marcoux, J., Guillet, V., Javaid, S., Burlet‐Schiltz, O., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.003444 · Cited by 11
de Man, S. M. A., & van Amerongen, R. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_522 · Cited by 11
“Although new compounds continue to be discovered, few of these drugs have progressed to clinical trials – a fate that is not uncommon for interventions aimed at targeting transcription factors in the nucleus (Darnell 2002; Chen and Koehler 2020a).”
DNA Vaccines Suppress Angiogenesis and Protect Against Growth of Breast Cancer Metastases
Mizutani, N., Luo, Y., Mizutani, M., Reisfeld, R., & Xiang, R. (2004) · Breast Disease · doi:10.3233/bd-2004-20110 · Cited by 11
“ate targets for anticancer drugs, provided selective inhibition of transcription can be applied rather than general inhibition which is expected to be too toxic [8].”
Verzele, D., & Madder, A. (2012) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201201235 · Cited by 11
Pathway Crosstalk Analysis of Microarray Gene Expression Profile in Human Hepatocellular Carcinoma
Zhou, X., Zheng, R., Zhang, H., & He, T. (2014) · Pathology & Oncology Research · doi:10.1007/s12253-014-9855-x · Cited by 11
“They are steroid receptors, resident nuclear proteins and latent cytoplasmic factors [31].”
BackgroundAntisense modulation of RNA processing as a therapeutic approach in cancer therapy
Spraggon, L., & Cartegni, L. (2013) · Drug Discovery Today Therapeutic Strategies · doi:10.1016/j.ddstr.2013.06.002 · Cited by 11
“Signal transducer and activator of transcription 3 (STAT3) is a member of the STAT family of transcription factors, which are key down-stream effectors of gene expression following cytokine, hormone or growth factor stimulation [65].”
BackgroundA novel non-phosphorylated potential antitumoral peptide inhibits STAT3 biological activity☆
Dourlat, J., Liu, W., Sancier, F., Edmonds, T., Pamonsinlapatham, P., Cruzalegui, F. H., & Garbay, C. (2009) · Biochimie · doi:10.1016/j.biochi.2009.05.006 · Cited by 13
Retention of Interstitial Genes between TMPRSS2 and ERG Is Associated with Low-Risk Prostate Cancer
Murphy, S. J., Kosari, F., Karnes, R. J., Nasir, A., Johnson, S. H., Gaitatzes, A., Smadbeck, J. B., Rangel, L. J., Vasmatzis, G., & Cheville, J. C. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0529 · Cited by 11
“However, although recurrent gene fusions involving ALK, ROS, MET, and ABL have been tremendously successful therapeutic targets in other cancers, fusions involving ETS-family of transcription factors have proven notoriously difficult to target (2, 17).”
BackgroundPrivalov, P. (2012) · Wiley eBooks · doi:10.1002/9781118337509.ch12 · Cited by 11
Nakaya, T., Aizawa, K., Taguchi, Y., Tsuji, K., Sekine, S., Murakami, K., Kasai, M., Nakano, H., Kondoh, Y., Dan, S., et al. (2022) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.1c00721 · Cited by 10
Dissection of the MEF2D-IRF8 transcriptional circuit dependency in acute myeloid leukemia
Pingul, B. Y., Huang, H., Chen, Q., Alikarami, F., Zhang, Z., Qi, J., Bernt, K. M., Berger, S. L., Cao, Z., & Shi, J. (2022) · iScience · doi:10.1016/j.isci.2022.105139 · Cited by 11
“Despite obstacles in developing TF specific inhibitors (Bushweller, 2019; Darnell, 2002) and no MEF2D/IRF8 inhibitor available, advances have been made via different strategies, including protein-protein interface disruption and PROTAC/molecular glue-based degradation (Henley and Koehler, 2021), and targeting the drug…”
BackgroundMethodRole of T‐box genes in cancer, epithelial‐mesenchymal transition, and cancer stem cells
Niu, G., Hao, J., Sheng, S., & Wen, F. (2021) · Journal of Cellular Biochemistry · doi:10.1002/jcb.30188 · Cited by 10
MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis
Katsarou, A., Trasanidis, N., Ponnusamy, K., Kostopoulos, I. V., Alvarez-Benayas, J., Papaleonidopoulou, F., Keren, K., Sabbattini, P. M. R., Feldhahn, N., Papaioannou, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023009772 · Cited by 11
Vicencio, E., Nuñez-Belmar, J., Cárdenas, J. P., Cortés, B. I., Martín, A. J. M., Maracaja‐Coutinho, V., Rojas, A., Cafferata, E. A., González, L., Vernal, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241914835 · Cited by 13
“Interestingly, there are reports of various master regulators identified in our research, including JUN , STAT3 , NFkB , TRP53 , FOS , E2F1 , and MyC , as modulators that affect cell proliferation, apoptosis, inflammatory activity, and tumor angiogenesis in various human cancer models [66,70,72].”
BackgroundApoptosis Induction by 13‐Acetoxyrolandrolide through the Mitochondrial Intrinsic Pathway
Acuña, U. M., Matthew, S., Pan, L., Kinghorn, A. D., Swanson, S. M., & de Blanco, E. J. C. (2013) · Phytotherapy Research · doi:10.1002/ptr.5091 · Cited by 10
Choi, M.-H., Jo, H., Kim, D., Yun, J., Kang, J. S., Kim, Y. S., Jung, J., Hong, J. T., Cho, J., Kwak, J., et al. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0737-5 · Cited by 12
Fontaine, F. R., Goodall, S., Prokop, J. W., Howard, C. B., Moustaqil, M. D., Kumble, S., Rasicci, D. T., Osborne, G. W., Gambin, Y., Sierecki, E., et al. (2018) · mAbs · doi:10.1080/19420862.2018.1451288 · Cited by 11
Neuroblastoma Pathology and Classification for Precision Prognosis and Therapy Stratification
Shimada, H., & Ikegaki, N. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812005-7.00001-1 · Cited by 10
Blaylock, R. L. (2019) · Surgical Neurology International · doi:10.25259/sni_361_2019 · Cited by 11
“Both NFκB and STAT3 are persistently activated in cancer cells, where they function as nuclear transcription factors required for activation of genes involved in tumor proliferation, survival, angiogenesis, immune evasion, and tumor invasion.[55,227] STAT3 is also involved in suppressing innate antitumor immunity by p…”
Morris, A., Hoyle, R. G., Pagare, P. P., Zaman, S. U., Ma, Z., Li, J., & Zhang, Y. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105812 · Cited by 10
SAP30, an oncogenic driver of progression, poor survival, and drug resistance in neuroblastoma
Prathipati, P., Pathania, A. S., Chaturvedi, N. K., Gupta, S. C., Byrareddy, S. N., Coulter, D. W., & Challagundla, K. B. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.03.014 · Cited by 10
Reconfigurable hybrid interface for molecular marker diagnostics and in-situ reporting
Ehrhardt, K., Guinn, M. T., Quarton, T., Zhang, M. Q., & Bleris, L. G. (2015) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2015.07.035 · Cited by 9
“AR is the mediator for androgens and is known to be involved in prostate cancer; it is therefore a target of therapeutics (Libermann and Zerbini, 2006; Darnell, 2002).”
BackgroundUnraveling the Mechanism of a Potent Transcriptional Activator
Lü, Z., Rowe, S. P., Brennan, B. B., Davis, S. E., Metzler, R. E., Nau, J. J., Majmudar, C. Y., Mapp, A. K., & Ansari, A. Z. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504895200 · Cited by 10
SIPAR negatively regulates STAT3 signaling and inhibits progression of melanoma
Ren, F., Su, F., Ning, H., Wang, Y., Geng, Y., Feng, Y., Wang, Y., Zhang, Y., Jin, Z. H., Li, Y., et al. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.07.023 · Cited by 10
Assessing the permissiveness of transcriptional activator binding sites
Rowe, S. P., & Mapp, A. K. (2008) · Biopolymers · doi:10.1002/bip.20946 · Cited by 15
N, R. C., Basappa, B., Srinivasa, V., Li, F., Siveen, K. S., Dai, X., Swamy, S. N., G, B. D., Sethi, G., Mantelingu, K., et al. (2013) · MedChemComm · doi:10.1039/c3md00119a · Cited by 11
STAT3 Inhibition as a Therapeutic Strategy for Chordoma
Owen, J. H. J., Abuzeid, W. M., Hervey‐Jumper, S. L., He, X., Gurrea‐Rubio, M., Lin, M., Altshuler, D. B., Keep, R. F., Prince, M. E., Carey, T. E., et al. (2016) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0036-1584198 · Cited by 10
Red Ginseng Oil Inhibits TPA-Induced Transformation of Skin Epidermal JB6 Cells
Truong, V., Kong, A. N. T., & Jeong, W. (2017) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4082 · Cited by 10
“21,22 Many studies have reported that both AP-1 and NF-j B may be implicated in the TPA-stimulated JB6 P + cell transformation.”
Shaik, S. P., Reddy, T. S., Sunkari, S., Rao, A. V. S., Babu, K. S., Bhargava, S. K., & Kamal, Ä. (2018) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520619666181127112621 · Cited by 10
Network-based drug repurposing for psychiatric disorders using single-cell genomics
Gupta, C., Kalafut, N. C., Clarke, D., Choi, J. J., Arachchilage, K. H., Khullar, S., Xia, Y., Zhou, X., Dursun, C., Gerstein, M., et al. (2025) · Cell Genomics · doi:10.1016/j.xgen.2025.101003 · Cited by 13
Potent selective inhibition of STAT 3 versus STAT 1 by cardiac hormones
Lane, M. L., Frost, C. D., Nguyen, J. P., Skelton, W. P., Skelton, M., & Vesely, D. L. (2012) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-012-1437-1 · Cited by 9
“STATs have been suggested to be logical targets for new anticancer agents [3].”
BackgroundPathology of Peripheral Neuroblastic Tumors
Shimada, H., Sano, H., & Hazard, F. K. (2020) · Imsang soa hyeoraek jong-yang/Imsang soa hyeol'aeg jong'yang/Clinical pediatric hematology-oncology · doi:10.15264/cpho.2020.27.2.73 · Cited by 9
Aberrant transcription factors in the cancers of the pancreas
Uddin, M. H., Al-Hallak, M. N., Philip, P. A., Chen, H., El‐Rayes, B. F., & Azmi, A. S. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.011 · Cited by 11
Rapid and convergent evolution in the Glioblastoma multiforme genome
Shpak, M., Goldberg, M. M., & Cowperthwaite, M. C. (2015) · Genomics · doi:10.1016/j.ygeno.2014.12.010 · Cited by 11
“significant enrichment for classes of proteins that play key roles in carcinogenesis and progression, among them transcription regulation and hormone binding [8], cell signaling [49], cytoskeletal genes such as dynein heavy chain [22,44] and cell membrane and adhesion elements such as mucins [16,11].”
BackgroundAnne, O., Jindal, D. A., Tamas, T. C., Lim, B. W. H., Pollard, D., & Xu, W. (2016) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.03.004 · Cited by 12
“Furthermore, CREB, c-Myb, MLL and c-Jun have been implicated in several cancers, including leukemias and solid tumors [31, 45-50]; thus compounds that block these proteins from forming key interactions with CBP may prove useful in the development of transcription targeted therapeutics [5, 51-59].”
BackgroundTranscriptional Regulation by the NFAT Family in Acute Myeloid Leukaemia
Patterson, S. D., Huang, X., Jørgensen, H. G., & Michie, A. M. (2021) · Hemato · doi:10.3390/hemato2030035 · Cited by 10
“Transcriptional regulators could be ideal therapeutic targets for AML, such that the effectors of multiple signalling pathways could be targeted simultaneously [13].”
BackgroundPossible Therapeutic Applications of Targeting STAP Proteins in Cancer
Matsuda, T., & Oritani, K. (2021) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b21-00672 · Cited by 9
Temporary Electrostatic Impairment of DNA Recognition: Light‐Driven DNA Binding of Peptide Dimers
Jiménez‐Balsa, A., Pazos, E., Martínez‐Albardonedo, B., Mascarenas, J. L., & Vázquez, M. E. (2012) · Angewandte Chemie · doi:10.1002/ange.201201627 · Cited by 9
TFinDit: transcription factor-DNA interaction data depository
Turner, D., Kim, R., & Guo, J. (2012) · BMC Bioinformatics · doi:10.1186/1471-2105-13-220 · Cited by 11
“; licensee BioMed Central Commons Attribution License (http://creativec reproduction in any medium, provided the or for diseases in which transcription factors play critical roles [3-5].”
BackgroundLiao, D., Li, W., Chen, J., Jiao, H., Zhou, H., Wang, B., & Yu, C. (2013) · Analytica Chimica Acta · doi:10.1016/j.aca.2013.08.022 · Cited by 9
Converting Inactive Peptides into Potent Transcriptional Activators
Lum, J. K., Majmudar, C. Y., Ansari, A. Z., & Mapp, A. K. (2006) · ACS Chemical Biology · doi:10.1021/cb600363n · Cited by 9
Jain, P., Shah, K., & Rishi, V. (2018) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2018.09.007 · Cited by 9
Breaking the Silence: The Interplay Between Transcription Factors and DNA Methylation
Baron, B. (2012) · InTech eBooks · doi:10.5772/55021 · Cited by 11
“They can be activated either di‐ rectly by tyrosine or serine kinases at the cell surface or by complex processes which include kinases along the pathway [117].”
BackgroundMa, S. L., Sørensen, A. B., Kunder, S., Sørensen, K. D., Quintanilla‐Martínez, L., Morris, D. W., Schmidt, J., & Pedersen, F. S. (2006) · Virology · doi:10.1016/j.virol.2006.05.006 · Cited by 9
“The constitutive expression of Icsbp modulates NF-κB stimulation through toll-like receptor (TLR) signaling, which could lead to tumor survival and inhibition of apoptosis (Bernal et al., 2001; Cahir-McFarland et al., 2000; Darnell, 2002).”
BackgroundBolotin, D., & Fuchs, E. V. (2003) · Nature · doi:10.1038/421594a · Cited by 10
Alexandari, A. M., Horton, C. A., Shrikumar, A., Shah, N., Li, E., Weilert, M., Pufall, M. A., Zeitlinger, J., Fordyce, P. M., & Kundaje, A. B. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.11.540401 · Cited by 16
“As TFs exert control over cellular differentiation and immune responses, they are implicated in cardiovascular diseases, inflammatory disorders, and many cancers and represent potential drug targets (1 – 4).”
Zhou, W., Xu, C., Yang, S., Li, H., Pan, C., Jiang, Z., Xie, L., Li, X., Qiao, H., Mi, D., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58795-2 · Cited by 14
Selective DNA‐Binding by Designed Bisbenzamidine‐Homeodomain Chimeras
Mosquera, J., Rodríguez, J., Vázquez, M. E., & Mascarenas, J. L. (2014) · ChemBioChem · doi:10.1002/cbic.201400079 · Cited by 8
Cancer Therapy Using Oligonucleotide-Based STAT3 Inhibitors: Will They deliver?
Kortylewski, M., & Nechaev, S. (2014) · Therapeutic Delivery · doi:10.4155/tde.13.152 · Cited by 8
The role and application of transcriptional repressors in cancer treatment
Park, M., Kang, K. W., & Kim, J. W. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01427-4 · Cited by 9
Natriuretic Peptides’ Metabolic Targets for Treatment of Cancer
Vesely, D. L. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e318292110a · Cited by 10
DNA Minor Groove Binders as Therapeutic Agents
Withers, J. M., Padroni, G., Pauff, S. M., Clark, A. W., Mackay, S. P., & Burley, G. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12561-2 · Cited by 8
Rare mutations provide unique insight into oncogenic potential of STAT transcription factors
Heppler, L. N., & Frank, D. A. (2017) · Journal of Clinical Investigation · doi:10.1172/jci98619 · Cited by 10
REGGAE: a novel approach for the identification of key transcriptional regulators
Kehl, T., Schneider, L., Kattler, K., Stöckel, D., Wegert, J., Gerstner, N., Ludwig, N., Distler, U., Schick, M., Keller, U. B., et al. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty372 · Cited by 9
“In cancer, many transcriptional regulators are known to be involved in tumor development and progression (Papavassiliou et al., 2016)(Nebert, 2002)(Darnell, 2002).”
BackgroundMani, G. S., Anchi, P., Sunkari, S., Donthiboina, K., Godugu, C., Shankaraiah, N., & Kamal, Ä. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127432 · Cited by 8
ROS, Redox Regulation, and Anticancer Therapy
Bansal, M. P. (2023) · Springer eBooks · doi:10.1007/978-981-99-7342-2_9 · Cited by 14
Yuan, L., Xi, H., Luo, Z., Liu, M., Chen, Q., Zhu, Q., Zhao, R., & Sheng, Y.-Y. (2024) · mSphere · doi:10.1128/msphere.00317-24 · Cited by 7
“Protein-DNA interactions are fundamental to the mechanics of transcriptional regulation (41).”
BackgroundLu, Z., Xiao, X., Zheng, Q., Wang, X., & Xu, L. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae366 · Cited by 8
“Evidence has linked multiple known diseases to the dysfunction of specific TRs [9, 10], highlighting the importance of identifying functional TRs in biological and medical research, which can aid the discovery of biomarker genes or potential therapeutic targets [11–13].”
BackgroundKounatidou, N. E., Vitkos, E. N., & Palioura, S. (2024) · The Ocular Surface · doi:10.1016/j.jtos.2024.11.006 · Cited by 11
Cui, Z., Huang, F., Fang, K., Yan, J., Zhang, Y., Kang, D. D., Zhou, Y., Zhao, Y., Everitt, J. I., Hankey, W., et al. (2025) · Advanced Science · doi:10.1002/advs.202417605 · Cited by 9
Targeting the MYCN-MDM2 pathways for cancer therapy: Are they druggable?
Wang, W., Du, Y., Datta, S., Fowler, J. F., Sang, H. T., Albadari, N. G., Li, W., Foster, J. H., & Zhang, R. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2023.101156 · Cited by 8
Advances in RNA therapeutics for modulation of ‘undruggable’ targets
Martinsen, E., Jinnurine, T., Subramani, S., & Rogne, M. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.003 · Cited by 7
Newman, J. A., Gavard, A. E., Imprachim, N., Aitkenhead, H., Sheppard, H. E., Poele, R. T., Clarke, P. A., Hossain, M. A., Temme, L., Oh, H. J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56213-1 · Cited by 9
“Directly targeting ligandless transcription factors as a cancer therapy has huge potential 35 , however, with a few notable exceptions 36 – 38 this potential has yet to be realized.”
Sun, Y., Zang, L., Lau, C., Zhang, X., & Lu, J. (2021) · Talanta · doi:10.1016/j.talanta.2021.122272 · Cited by 7
Peptide scalpels for site-specific dissection of the DNA–protein interface
Verzele, D., Carrette, L. L. G., & Madder, A. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.03.001 · Cited by 7
“Truncated mimics that lack, for example, the activation domain while retaining the DNA-binding requirements might interfere with DNA-complexation of the malignant natural counterpart, disrupt transcriptional induction and ultimately suppress the oncogenic activity [1-2].”
BackgroundSmall‐Molecule Probes to Target the Human Mediator Complex
Phillips, A. J., & Taatjes, D. J. (2013) · Israel Journal of Chemistry · doi:10.1002/ijch.201300039 · Cited by 8
Özer, B., & Sezerman, O. U. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s12-s7 · Cited by 9
“Moreover, since post-translational modification and regulation of transcription pathways are critical for cancer diagnosis and therapy [67,68], we have searched for transcription factors in TFCat database [54] and as a result, 207 out of 2826 genes (7.”
BackgroundZhao, Y., & Liu, Y. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.12.027 · Cited by 7
Misra, S. K., Kampert, T. L., & Pan, D. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00117 · Cited by 7
Riechers, A., Grauer, A., Ritter, S., Sperl, B., Berg, T., & König, B. (2009) · Journal of Molecular Recognition · doi:10.1002/jmr.986 · Cited by 7
Yu, H., Mitra, R., Yang, J., Li, Y., & Zhao, Z. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4762-7 · Cited by 8
Statistical Feature Selection : With Applications in Life Science
Nilsson, R. (2007) · DiVA (Linkoping University) · Cited by 11
Diao, S., Li, L., Zhang, J., Ji, M.-L., Sun, L., Shen, W., Wu, S., Chen, Z., Huang, C., & Li, J. (2025) · Biochemical Pharmacology · doi:10.1016/j.bcp.2025.116884 · Cited by 7
“Macrophages are essential immune cells in the immune system 24–27 .”
Gene Therapy Approaches for Atherosclerosis Focusing on Targeting Lipid Metabolism and Inflammation
Bezsonov, E. E., Chernyi, N., Saruhanyan, M., Shimchenko, D., Bondar, N., Gavrilova, D., Baig, M. S., & Malogolovkin, A. S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26146950 · Cited by 11
“This approach is of in-Int terest for diseases that require regulation of “untreatable” targets: transcription factors or growth factors [167].”
Rodak, O., Mrozowska, M., Rusak, A., Gomułkiewicz, A., Piotrowska, A., Olbromski, M., Podhorska‐Okołów, M., Ugorski, M., & Dzięgiel, P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411316 · Cited by 6
“In diseases, such as cancer, the survival of tumour cells requires the reprogramming of molecular network to maintain constant cell divisions during starvation or hypoxic conditions [36].”
BackgroundMyeloid ectopic viral integration site 2 accelerates the progression of Alzheimer's disease
Cui, Y., Zhang, X., Liu, J., Hou, Y., Qiao, S., Cao, M., Zhang, J., Wang, X., Liu, C., Wang, P., et al. (2024) · Aging Cell · doi:10.1111/acel.14260 · Cited by 6
He, M., Yang, Q., Norvil, A. B., Sherris, D., & Gowher, H. (2018) · Molecules · doi:10.3390/molecules23071615 · Cited by 6
Jie, Z., Wang, S., Ma, Q., Shen, Y., Zhao, X., Yu, H., Xie, Z., & Jiang, C. (2022) · Journal of bone oncology · doi:10.1016/j.jbo.2022.100439 · Cited by 6
Lind, J., Aksoy, O., Prchal‐Murphy, M., Fan, F., Fulciniti, M., Stoiber, D., Bakiri, L., Wagner, E. F., Zwickl-Traxler, E., Sattler, M., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01117-4 · Cited by 8
“To address this problem, PROTeolysis Targeting Chimeric molecule (PROTAC) technology has emerged as maybe the most exciting, innovative approach to target TFs by protein degradation [5, 26, 38].”
BackgroundThe Molecular Biology of Brain Metastasis
Woditschka, S., Gril, B., Evans, L. M., Reed, L. T., & Steeg, P. S. (2012) · Cancer metastasis · doi:10.1007/978-94-007-5291-7_2 · Cited by 7
Regulatory variation: an emerging vantage point for cancer biology
Li, L., Lorzadeh, A., & Hirst, M. (2013) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1250 · Cited by 5
The development of myelin repair agents for treatment of multiple sclerosis: Progress and challenges
Murphy, R., Murphy, K. J., & Pickering, M. (2013) · Bioengineered · doi:10.4161/bioe.22835 · Cited by 6
Moving Toward Personalized Medicine in Castration-Resistant Prostate Cancer
Allen, E. M. V., & Pomerantz, M. M. (2012) · Urologic Clinics of North America · doi:10.1016/j.ucl.2012.07.005 · Cited by 6
Imaging Protein-Protein Interactions in Whole Cells and Living Animals
Piwnica-Worms, D., & Luker, K. E. (2006) · Springer eBooks · doi:10.1007/3-540-26809-x_2 · Cited by 8
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.